feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    UID:
    kobvindex_HPB1256238606
    Format: 1 online resource (363 p.)
    ISBN: 9783030632342 , 3030632342
    Content: This open access book discusses the most current issues in head and neck cancer with a focus on current trends such as biomarkers, precision medicine and immunotherapy. New approaches in the diagnosis such as liquid biopsies and imaging biomarkers to predict radiotherapy toxicity as well as approaches in the surgical management of head and neck cancers are discussed. The book discusses medical and surgical approaches in both primary, recurrent and metastatic disease and also covers approaches for rare head neck cancers. Readers will learn about the latest drug developments and epidemiological aspects in cancers ranging from head and neck squamous cell cancer to nasopharynx cancer. Edited by a team of world leaders in head and neck cancer, this volume serves as an easy reference to the head and neck oncology practitioner and provides a contemporary overview for specialists the field. The chapters are based on the latest data presented at the 7th Trends in Head and Neck Oncology Conference and reflect the most up-to-date information in the field.
    Note: Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) -- Promising biomarkers for early diagnosis and prognosis prediction in HNS -- Biomarkers to predict radiotherapy toxicity -- Biomarkers for hypoxia, HPVness and proliferation from imaging perspective -- Mechanism of cetuximab resistance and how to overcome it -- The role of liquid biopsy for monitoring disease evolution -- NK cells in immunotherapy: how important are they? -- Biomarkers for immune modulatory treatment in HNSCC -- Primary disease (1) -- Novel approaches in surgical management of HNSCC -- The surgical approach to elderly patients with HNSCC -- The nonsurgical approach to locoregionally advanced HNSCC -- High-dose three-weekly or low-dose weekly cisplatin during radiation, what to prefer? -- Primary disease (2) -- Where and when to use induction chemotherapy? -- Prognostic role of p16/HPV in non-oropharyngeal head and neck cancer -- Is there a role for neoadjuvant targeted and immunotherapies? -- Is there a role for adjuvant targeted and immunotherapies? -- Optimal supportive measures during primary treatment -- Precision Medicine in head and neck cancer: myth or reality -- Recurrent and / or metastatic disease -- Salvage surgery: candidates, safe reconstruction, and results? -- Re-irradiation for local relapses or second primaries: when and how? -- New promising targeted agents in first and second-line settings -- Update of immune therapies in recurrent/metastatic HNSCC -- Special Issue -- Patients with rare head neck cancers: do they need a different approach? .-Nasopharynx cancer -- New epidemiological aspects -- New developments in the management of nasopharyngeal carcinoma -- New drugs for recurrent/metastatic nasopharynx cancer.
    Additional Edition: Print version: Vermorken, Jan B. Critical Issues in Head and Neck Oncology Cham : Springer International Publishing AG,c2021 9783030632335
    Language: English
    Keywords: Electronic books. ; Electronic books. ; Conference papers and proceedings.
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    UID:
    kobvindex_HPB1375084527
    Format: 1 online resource (ix, 365 pages) : , illustrations (some color)
    ISBN: 9783031231759 , 3031231759
    Content: This is an open access book. With a wealth of exciting data emerging in this rapidly evolving field this book will review the state-of-the-art knowledge with emphasis on multidisciplinary decision and management of head and neck cancer. The book provides significant detail on a wide range of topics including: the role of new targets for treatment, immunotherapy, resistance mechanisms, standardizing molecular profiling programs, and new methods to guide therapeutic approaches. In addition different disease situations are addressed including different treatment approaches in primary disease and in recurrent and/or metastatic disease as well as new developments in pathology, surgery and reconstruction techniques, new systemic therapies in salivary gland cancer, and supportive care and follow-up. All disciplines involved in the treatment of head & neck cancer are covered with a focus on translation into daily practice. The 8th-THNO is designed for medical oncologists, head and neck surgeons, radiation oncologists, otolaryngologists, and other medical professionals involved in the treatment of patients with head and neck cancer.
    Note: The gut microbiota and anticancer immunotherapy, Laurence Zitvogel -- The bidirectional communication between tumor cells and other components of the tumor microenvironment, Phil Sloan -- Resistance mechanisms in immune checkpoint inhibitors and radiotherapy and how to overcome this, Kirsten Lauber -- DNA repair mechanisms as a new target in head and neck cancer, Kevin Harrington -- How to standardize molecular profiling programs for routine patient care, Ingeborg Tinhofer -- Novel immune oncology targets beyond PD-1/PD-L1 in head and neck cancer, Christophe Le Tourneau -- Analytic methods to understand head and neck cancer evolution to guide therapeutic approaches, Ben O’Leary -- Clinical cases, Jean Pascal Machiels -- Updates from the European Head & Neck Society (EHNS), Wojciech Golusinski (President of EHNS) Section 2: Primary disease Piero Nicolai -- Sensitivity and specificity of extranodal extension in SCCHN: unlocking the strongest prognostic factor in head and neck cancer, Brian O’Sullivan -- From photon to proton: what’s in it for head and neck cancer patients?, Volker Budach -- Lessons learned from RTOG 1016 and DE-ESCALaTE: what’s next?, Hisham Mehanna.-Treatment intensification in LA-SCCHN: what are the options and for who?, Jan Vermorken -- Immune checkpoint inhibitors in the curative setting: preclinical and clinical data, Jean-Pascal Machiels -- Carcinoma of unknown primary: diagnostics and the potential of transoral surgery, René Leemans -- Clinical cases, Volker Budach -- Individualized therapy in 1-line R/M-SCCHN: what selection criteria should we use?, Petr Szturz -- Patterns of response to immune oncology drugs: how relevant are they in SCCHN?, Amanda Psyrri -- The role of radiotherapy in oligometastatic or oligoprogressive disease in R/M-SCCHN, Daan Nevens -- Updates from the EORTC Head and Neck Cancer Group (HNCG), Jean-Pascal Machiels (Chair of EORTC-HNCG) -- Real world evidence in head and neck cancer, Anil D'Cruz (UICC president -- Pathology driven treatment of skull base tumors, Piero Nicolai -- Modern day reconstruction of facial bones, Sat Parmar -- Targeting molecular/minimal residual disease using novel technologies and clinical trials design, Lillian Siu -- New developments in surgery for malignant salivary gland tumors, Jeroen Meulemans -- New systemic therapies in salivary gland cancer, Ethan Argiris. Exercise and nutrition interventions in head and neck cancer, Paolo Bossi -- Telehealth intervention in head and neck cancer patients: a promise?, Irma Verdonck-de Leeuw.
    Additional Edition: ISBN 3031231740
    Additional Edition: ISBN 9783031231742
    Language: English
    Keywords: Electronic books.
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages